On February 27 and 28, 2020, Joseph H. (Jody) Hunt, Assistant Attorney General for DOJ’s Civil Division, and Michael Granston, Deputy Assistant Attorney General, Commercial Litigation Branch, spoke about False Claims Act (“FCA”) enforcement at the Federal Bar Association’s annual Qui Tam Conference in Washington, D.C. They highlighted FCA enforcement priorities for 2020, and offered insights on the Department’s dismissal policy and cooperation policy – two topics that Deputy Associate Attorney General Stephen Cox also addressed in remarks earlier this year.

Enforcement Priorities

During his remarks, Assistant AG Hunt highlighted three priorities for FCA enforcement in 2020: (1) fraud involving Medicare Advantage plans, which serve approximately one third of all Medicare beneficiaries; (2) new opportunities for fraud that have arisen in the context of electronic health records; and (3) fraud that affects nursing homes or nursing home patients.

Deputy Assistant AG Granston also indicated that attendees should expect to see additional FCA enforcement actions directed at schemes involving telemedicine and genetic testing. Outside of health care, Deputy Assistant AG Granston noted that trade restrictions and duties are a current focus throughout the Department, and noncompliance may expose companies to reverse false claims liability.

Dismissal

Assistant AG Hunt and Deputy Assistant AG Granston discussed the Department’s policy regarding dismissal pursuant to 31 U.S.C. § 3730(c)(2)(A), first described in the so-called “Granston Memo,” and later incorporated into the Justice Manual. Consistent with Deputy Associate AG Cox’s comments earlier this year, they placed the post-Memo uptick in the number of (c)(2)(A) dismissals in context. Since January 1, 2018, the United States has moved to dismiss approximately 45 cases. By comparison, approximately 1,100 qui tam actions were filed during that period. The Department’s exercise of its authority has been, and will remain, judicious.

Assistant AG Hunt and Deputy Assistant AG Granston addressed several other issues related to the Department’s approach to dismissal:

  • Burden: Consistent with prior statements by the Department, they reiterated that the burden on the government is a factor that the Department will consider with respect to dismissal, but it is not the only factor. The United States will not seek to dismiss an otherwise meritorious case solely because the case will require the government to expend resources. They also cautioned that the government has tools that it will use to respond to overly aggressive discovery, including seeking reimbursement and filing for protective orders.
  • Merits and Government Interest: They stressed that the merits of the action and the potential impact on government interests are two important factors informing the government’s dismissal decision. Assistant AG Hunt noted that the Department’s dismissal analysis has similarities to the intervention analysis and may include considerations such as whether the case is based on a violation of a binding legal requirement (i.e. a statute, regulation, or contract). Deputy Associate AG Cox spoke more expansively on the role of sub-regulatory guidance in FCA enforcement during his remarks earlier this year. 
  • Timing Related To Dismissal: The Department’s dismissal decision is not static – it may be fluid and adjusted over the course of the matter. At the same time, defendants should think carefully about the timing of when they request meetings with supervisors and other senior lawyers to address these issues, as it is unlikely that they will have multiple opportunities for such a meeting.
  • Partial Dismissal: It is the Department’s view that the government can seek dismissal of only part of the case; it is not an all-or-nothing proposition.

Cooperation

Pointing to the FCA cooperation policy announced last year, Assistant AG Hunt also reiterated the Department’s willingness to provide credit to corporate defendants for voluntarily disclosing misconduct, cooperating with law enforcement, and taking meaningful remedial measures. He identified a defendant’s assistance with assessing the scope of potential damages as an example of cooperation that can be especially meaningful, a notion that other government lawyers echoed throughout the conference.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Christopher Denig Christopher Denig

Chris Denig, who has been named by The American Lawyer as “Litigator of the Week” for his False Claims Act litigation work, represents major corporations, boards of directors, and senior executives in high stakes government enforcement matters, sensitive internal investigations, and…

Chris Denig, who has been named by The American Lawyer as “Litigator of the Week” for his False Claims Act litigation work, represents major corporations, boards of directors, and senior executives in high stakes government enforcement matters, sensitive internal investigations, and complex False Claims Act investigations and litigation, as well as other litigation and compliance matters. Chris was co-lead counsel in U.S. ex rel. Polansky v. Executive Health Resources (EHR) an important False Claims Act case, successfully representing EHR in the EDPA, Third Circuit, and ultimately a win in the United States Supreme Court.  

As a partner in the White Collar Defense and Investigations practice, Chris routinely represents clients before the U.S. Department of Justice, Securities & Exchange Commission, Congress, State Attorneys General, and other law enforcement and regulatory agencies. Chris has advised clients in the life sciences, financial services, defense, technology, Gaming, and manufacturing industries on a variety of white collar matters including those relating to corporate whistleblowers, cybersecurity, accounting fraud, insider trading, export controls, foreign bribery, government contracting, the Animal Welfare Act, and Clean Water Act.

He regularly represents major pharmaceutical and medical device companies with issues relating to current Good Manufacturing Practices (cGMP), off-label promotion, kickbacks, Park issues, state consumer protection/unlawful trade practices issues, as well as False Claims Act and other civil litigation.

Chris clerked for Judge Richard M. Berman of the U.S. District Court for the Southern District of New York. He earned his J.D. from Columbia Law School and B.A. from Swarthmore College.

Photo of Matthew Dunn Matthew Dunn

Matt Dunn’s practice focuses on white collar defense and litigation, with a particular emphasis on representing healthcare companies. He has extensive experience representing companies in federal and state criminal and civil investigations by the Department of Justice and other enforcement agencies. His complementary…

Matt Dunn’s practice focuses on white collar defense and litigation, with a particular emphasis on representing healthcare companies. He has extensive experience representing companies in federal and state criminal and civil investigations by the Department of Justice and other enforcement agencies. His complementary litigation practice focuses on defending companies in government-facing litigation, such as cases arising under the False Claims Act and state consumer fraud laws, and follow-on litigation arising from government investigations. Matt received his law degree from Columbia Law School, his master of science degree from Troy University, and his undergraduate degree from Vanderbilt University.

Prior to becoming an attorney, Matt was a captain in the United States Air Force.

Photo of Krysten Rosen Moller Krysten Rosen Moller

Krysten Rosen Moller focuses her practice on representing clients in internal investigations, government investigations, and follow-on civil litigation, with an emphasis on serving clients in the life sciences and healthcare industries.

Krysten assists companies with complex internal and government investigations covering a broad…

Krysten Rosen Moller focuses her practice on representing clients in internal investigations, government investigations, and follow-on civil litigation, with an emphasis on serving clients in the life sciences and healthcare industries.

Krysten assists companies with complex internal and government investigations covering a broad range of issues, including fraud and abuse, advertising and promotion, and bribery and corruption. Krysten has particular experience conducting targeted and efficient internal investigations and representing pharmaceutical and medical device companies against investigations from the Department of Justice or other government regulators. Krysten’s complementary litigation practice focuses on defending life sciences and healthcare companies in related litigation, including cases arising under the False Claims Act and other follow-on litigation arising from government investigations.

Krysten also counsels clients on compliance matters. She regularly represents companies negotiating HHS OIG Corporate Integrity Agreements (CIAs) and advises companies on implementing and operating under CIAs. She has also conducted False Claims Act risk assessments and advised on other fraud and abuse issues.